Kent D. Stewart

High Point University — United States

Medicine · Health Sciences

42h-index5.2kcitations138works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(24), Peptidase Inhibition and Analysis(20), HIV Research and Treatment(17), HER2/EGFR in Cancer Research(12), Cancer-related Molecular Pathways(11)

Publications138 total

Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
Journal of Medicinal Chemistry·2023· 10 citedOpen Access
Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
2023Open Access
Pharmacology and Therapeutic Potential of Dopamine D4 Receptor Antagonists for Cocaine Use Disorder
2022Open Access
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a <i>trans</i>-Stilbene Analog with Good Oral Bioavailability
Journal of Medicinal Chemistry·2018· 18 cited
CCDC 707824: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2015· 17 cited
THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects
Annals of the Rheumatic Diseases·2014· 36 cited
Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: Synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif
Bioorganic & Medicinal Chemistry Letters·2013· 11 cited
Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195
ACS Medicinal Chemistry Letters·2013· 29 citedOpen Access
Gsk-3beta with inhibitor 6-chloro-N-cyclohexyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine
2013
Design and synthesis of tricyclic cores for kinase inhibition
Bioorganic & Medicinal Chemistry Letters·2012· 22 citedOpen Access
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
European Journal of Cancer·2012· 15 cited
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 14 citedOpen Access
The Drug Guru Project
2012· 1 cited
Contribution of indazolinone tautomers to kinase activity
Bioorganic & Medicinal Chemistry Letters·2012· 2 citedOpen Access
Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 5 citedOpen Access
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases
Bioorganic & Medicinal Chemistry Letters·2012· 19 citedOpen Access
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
Bioorganic & Medicinal Chemistry Letters·2012· 30 citedOpen Access
Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
Molecular Cancer Therapeutics·2011· 1 cited
Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases
Bioorganic & Medicinal Chemistry Letters·2011· 49 cited
page 1 of 7Next →

Frequent Co-authors

Hing L. Sham(14), Dale J. Kempf(9), Vincent S. Stoll(9), Warren M. Kati(7), Jennifer J. Bouska(7), Akhteruzzaman Molla(7), Thomas J. Sowin(7), Kennan C. Marsh(6), Steven K. Davidsen(6), Vincent L. Giranda(6), Zhonghua Pei(6), Thomas W von Geldern(6), Kenton L. Longenecker(6), Thomas Lübben(6), Stephen J. Ballaron(6), David W. A. Beno(6), Anita J. Kempf-Grote(6), James M. Trevillyan(6), Daniel H. Albert(5), Keith B. Glaser(5)